Inventor · disambiguated record
Gregory William Endres
Also filed as: ENDRES GREGORY W · ENDRES GREGORY WILLIAM
22 granted patents·7 pending applications·49 citations·filing 2000–2022
92Inventor score
Files withCAYMAN CHEMICAL CO INC21ENDRES GREGORY W2PINPOINT TESTING LLC2BARRETT STEPHEN DOUGLAS1BARTA NANCY S1
Top patents by PatentIndex Score
29 records- 0187US6410622B1Method of preventing fouling organisms in marine environments and polymer-bound nitric oxide/nitric oxide-releasing compositions usable thereforFiled 2000·Granted Jun 25, 2002·28 cites·20 claims
- 0286US9487478B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2015·Granted Nov 8, 2016·4 cites·21 claims
- 0385US9180116B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Nov 10, 2015·6 cites·20 claims
- 0482US9440919B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Sep 13, 2016·4 cites·23 claims
- 0580US9701630B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Granted Jul 11, 2017·2 cites·20 claims
- 0677US11884624B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2021·Granted Jan 30, 2024·0 cites·3 claims
- 0775US9890104B2Amine salts of a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2014·Granted Feb 13, 2018·1 cites·10 claims
- 0873US11066361B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2020·Granted Jul 20, 2021·0 cites·3 claims
- 0973US9908834B2Methods of synthesizing a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2017·Granted Mar 6, 2018·1 cites·4 claims
- 1072US8536185B2Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseasesENDRES GREGORY W·Filed 2009·Granted Sep 17, 2013·2 cites·57 claims
- 1167US10556862B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2018·Granted Feb 11, 2020·0 cites·4 claims
- 1265US10155716B2Amine salts of a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2017·Granted Dec 18, 2018·0 cites·99 claims
- 1362US9120820B2Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteinsBARRETT STEPHEN DOUGLAS·Filed 2012·Granted Sep 1, 2015·1 cites·7 claims
- 1459US10450257B2Methods of synthesizing a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2018·Granted Oct 22, 2019·0 cites·14 claims
- 1559US2017066751A1Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Application pending·0 cites
- 1659US2020002261A1Methods of synthesizing a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2019·Application pending·0 cites
- 1758US9126973B2Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2014·Granted Sep 8, 2015·0 cites·51 claims
- 1856US2015315114A1Methods of Synthesizing a Prostacyclin AnalogCAYMAN CHEMICAL CO INC·Filed 2013·Application pending·0 cites
- 1954US2025224410A1Ready-to-constitute analytical platforms for chemical analyses and quantification of analytes in biological samplesPINPOINT TESTING LLC·Filed 2022·Application pending·0 cites
- 2053US2013079375A1Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2012·Application pending·0 cites
- 2149US12019002B2Ready-to-extract platforms for chemical analysis and quantification of unknown samples using spiked matrix standardsPINPOINT TESTING LLC·Filed 2020·Granted Jun 25, 2024·0 cites·6 claims
- 2249US10729810B2Methods, systems, and compositions for promoting bone growthCAYMAN CHEMICAL CO INC·Filed 2014·Granted Aug 4, 2020·0 cites·16 claims
- 2347US9676712B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 13, 2017·0 cites·24 claims
- 2447US8440417B2Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthasePALACKAL NISHA·Filed 2009·Granted May 14, 2013·0 cites·1 claims
- 2546US2015322107A1Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteinsCAYMAN CHEMICAL CO INC·Filed 2015·Application pending·0 cites
- 2646US2015323542A1Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteinsCAYMAN CHEMICAL CO INC·Filed 2015·Application pending·0 cites
- 2743US8680327B2Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolitesENDRES GREGORY W·Filed 2011·Granted Mar 25, 2014·0 cites·13 claims
- 2843US8063240B2Prostaglandin E1 and E2 analogs for the treatment of various medical conditionsBARTA NANCY S·Filed 2008·Granted Nov 22, 2011·0 cites·14 claims
- 2942US9688627B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 27, 2017·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Gregory William Endres files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →